ABNewswire - Press Release Distribution Service

Thursday, February 26, 2026

From Ulta Beauty in the U.S. to Rossmann in Europe: AROMATICA Leads the "K-Scalp" Craze

Strengthening Global Brand Awareness through Strategic Expansion into North American and European Markets

AROMATICA, an aromatherapy-based scalp and skincare brand at the forefront of the global skinification movement, is expanding the reach of Korean scalp care through new retail partnerships with Ulta Beauty in North America and Rossmann in Europe.

The brand is set to introduce 10 scalp and hair care products on Ulta Beauty’s online platform, the largest specialty beauty retailer in the United States, further strengthening its presence in the North American market. Products including Rosemary Scalp Scaling Shampoo, Rosemary Root Enhancer and Quinoa Protein Shampoo are formulated to meet growing U.S. consumer demand for clean, performance-driven beauty solutions.

In Europe, AROMATICA is launching four scalp care products through approximately 170 Rossmann offline stores and its online platform in the Czech Republic, while further expanding into Poland through Rossmann’s online channel. This move marks a strategic step in broadening the brand’s footprint across Eastern Europe.

Powered by rosemary essential oil–based formulations, AROMATICA’s signature products emphasize scalp nourishment and improved scalp condition, resonating with global consumers seeking healthier scalp environments and solutions for hair thinning. In particular, Rosemary Root Enhancer has gained strong traction across online beauty channels in the U.S. and Europe, strengthening its position as a key product within the brand’s global scalp care portfolio.

“The emergence of Korean scalp care as a new pillar of K-beauty reflects rising global interest in products that combine efficacy with clean beauty standards,” said a representative from AROMATICA. “Through these strategic retail partnerships, we aim to deepen our connection with global consumers and continue expanding our international presence.”

Founded in 2004, AROMATICA has steadily grown its global business by exporting clean beauty products based on natural, organic and vegan ingredients to 34 countries worldwide. Its expansion into major retail channels in North America and Europe underscores the growing recognition of Korean scalp care as a distinct and evolving category within the global beauty market.

Media Contact
Company Name: WWDSTUDIOSPR
Contact Person: Jihyeon Kim
Email:Send Email
Country: South Korea
Website: https://bit.ly/4pIUi5g

Step Ahead ABA Supports Families in Kapolei, HI with Tailored ABA Therapy Programs

ABA Therapy in Kapolei HI

Step Ahead ABA offers personalized ABA therapy programs to support families in Kapolei, HI, helping children with autism reach their full potential.

Kapolei, HI - Step Ahead ABA, a trusted provider of community-based Applied Behavior Analysis (ABA) therapy, is excited to expand its services to families in Kapolei, HI. The company offers personalized therapy programs tailored to meet the unique needs of children with autism, emphasizing growth, independence, and confidence through flexible, real-world interventions.

Focused on Real-World Skill Development

ABA Therapy in Kapolei HI, Community-based therapy services are designed to integrate seamlessly into children’s daily routines. By providing therapy in the home or community settings, Step Ahead ABA ensures that children can practice essential skills in familiar environments. This approach fosters greater independence and lasting change, as children apply what they learn in their natural surroundings.

“We understand the importance of providing therapy in real-world settings where children can immediately apply their skills,” said Heather Mocny, CEO of Step Ahead ABA. “Our personalized programs are designed to meet each child’s unique needs, and we are proud to offer a flexible, family-centered approach to therapy that promotes success.”

Personalized Care for Every Child

At ABA Therapy in Kapolei, each child’s therapy plan is customized to address their specific goals, including communication and social skills, behavior management, and more. The company uses evidence-based practices to develop effective interventions, ensuring progress is measurable and meaningful. With a focus on individualized care, Step Ahead ABA helps children thrive in real-life situations.

Unlike traditional therapy models, Step Ahead ABA eliminates long waitlists and rigid scheduling. The company offers flexible appointment times to accommodate families, making therapy an integrated part of daily life. This approach makes therapy more accessible and less disruptive, offering families a seamless experience.

“Step Ahead ABA has been a game-changer for us,” said a parent of one of Step Ahead ABA’s clients. “The therapy has made such a difference in our child’s development. We can see the progress every day, and the team’s support has been invaluable.”

Serving the Kapolei Community

Kapolei ABA Therapy is now serving families in Kapolei, HI, with a focus on providing flexible, accessible therapy options. The company’s approach ensures that children and families receive the best possible care, helping them reach their full potential through personalized ABA therapy. Families in Kapolei can now enjoy the benefits of community-based therapy in the comfort of their homes.

About Step Ahead ABA:

Step Ahead ABA is a provider of community-based ABA therapy services, committed to offering personalized care for children with autism. With over 5 years of experience, Step Ahead ABA delivers flexible, evidence-based therapy that helps children achieve meaningful growth and development. The company provides individualized services to families across multiple states, ensuring that therapy is both effective and integrated into everyday life.

Media Contact
Company Name: Step Ahead ABA
Contact Person: Jay Levin
Email:Send Email
Phone: (888) 238-3072
State: Hawaii
Country: United States
Website: stepaheadaba.com

New Platform Launches to Help Digital Nomad Families Find Alternative Schools Worldwide

New platform Nomadschoolers helps digital nomad families find alternative schools, Waldorf communities, Montessori programmes, and forest schools worldwide. With 200+ listings across dozens of countries and new projects added daily, it is free to use at nomadschoolers.com.

Nomadschoolers.com launches with over 200 alternative schools, Waldorf communities, Montessori programmes, and forest schools listed across dozens of countries - with new projects added daily.

Nomadschoolers, a new platform connecting digital nomad families with alternative schools, Waldorf and Montessori communities, forest schools, and educational co-ops worldwide, has officially launched. Founded by Mads Lontoft and Nikolaj Astrup, the platform already lists more than 200 projects across the globe, with new listings being added every day.

The rise of remote work has given families unprecedented freedom to choose where - and how - their children learn. Yet finding high-quality, values-aligned alternative schools abroad has remained frustratingly difficult. Nomadschoolers solves this by creating the first dedicated, searchable directory of alternative and international educational communities, complete with detailed information on curriculum, location, cost of living, climate, and logistics - everything a family needs to relocate with children.

“Through running Traveling Village, I’ve spoken with hundreds of families from around the world. The same desire keeps coming up: a more balanced family life, stronger community, and an education that actually fits how they live. Nomadschoolers exists to make that possible.”
- Nikolaj Astrup, Co-founder, Nomadschoolers

Lontoft and Astrup are not newcomers to education and community-building. Nearly two decades ago, they co-founded a print magazine on entrepreneurship for young people, distributed free to high schools across Denmark. Astrup later founded Traveling Village, an initiative that takes groups of around 20 families to live and travel together for four-month stints — giving him rare, ground-level insight into exactly what nomad families need.

Each listing on Nomadschoolers goes beyond a simple school profile. The platform provides families with air quality data, walkability scores, internet speed, healthcare proximity, cost-of-living breakdowns, and visa information - everything needed to make a realistic, informed decision about relocating with children. Schools, Waldorf communities, Montessori programmes, and alternative education projects can also list directly on Nomadschoolers, reaching families who are already aligned with their values and approach.

Nomadschoolers is free to use for families and available now at nomadschoolers.com.

About Nomadschoolers

Nomadschoolers is a platform helping location-independent families discover alternative and international educational communities around the world. With over 200 listed projects and growing, the platform covers Waldorf, Montessori, forest schools, democratic schools, and other innovative educational models across dozens of countries. Founded in 2026 by Mads Lontoft and Nikolaj Astrup.

Media Contact
Company Name: Nomadschoolers
Contact Person: Nikolaj Astrup Madsen
Email:Send Email
Country: Denmark
Website: https://nomadschoolers.com

The Growing Need for ABA Therapy in Phoenix: How Children’s Specialized ABA is Meeting the Demand

aba therapy phoenix az

Children's Specialized ABA in Phoenix is addressing the rising demand for ABA therapy, providing essential services to support children with autism and developmental delays.

Phoenix, AZ - The increasing demand for specialized services for children diagnosed with autism has led to a rise in the need for effective therapy options. In response to this growing need, Children’s Specialized ABA, a trusted provider of Applied Behavior Analysis (ABA) therapy, is expanding its services to Phoenix. This expansion aims to provide families with high-quality, individualized therapy that helps children thrive.

Addressing the Demand for ABA Therapy

Autism diagnoses continue to rise, and as a result, more families are seeking evidence-based therapies to support their child’s development. ABA therapy in Phoenix AZ is one of the most effective treatment methods, known for its ability to improve skills in communication, social interactions, and behavior. It is widely recognized as a highly successful approach for children with autism.

Children’s Specialized ABA has long been a leader in providing personalized ABA therapy services. With multiple locations across New Jersey, Maryland, and North Carolina, the company is expanding into Phoenix to meet growing demand there. The company provides both center-based and home-based therapy options, offering flexibility to ensure each child receives the best possible care.

A Personalized Approach to Therapy

At the core of ABA therapy Phoenix services their commitment to individualized care. Each child’s therapy plan is customized based on their specific needs, strengths, and learning style. The therapy is designed to provide the most effective treatment possible, helping children achieve their full potential.

The company’s team of Board Certified Behavior Analysts (BCBAs) works closely with families to create personalized treatment plans. This collaboration ensures that therapy is tailored to meet each child’s unique needs. The new Phoenix location will offer in-home therapy services, allowing children to receive care in a familiar, comfortable environment where they can make the most progress.

“Our mission is to partner with families to provide the support and tools they need for their child’s success,” said Miriam Newmark, Chief Operating Officer of Children’s Specialized ABA. “We are here to help children reach their full potential and provide families with the resources they need to make a meaningful difference.”

Expanding Services to Meet the Need

Children’s Specialized ABAs’ expansion marks an important step toward making high-quality Phoenix ABA therapy more accessible to families in the area. The company is committed to continuing its growth and to providing the best possible care to children across multiple states.

About Children’s Specialized ABA

Children’s Specialized ABA is a leading provider of Applied Behavior Analysis therapy for children diagnosed with autism. With locations across several states, the company offers both center-based and home-based therapy services, ensuring every child receives personalized care to help them reach their potential.

Media Contact
Company Name: Children's Specialized ABA
Contact Person: Miriam Newmark
Email:Send Email
Phone: 201-719-8222
Address:500 Redland Court, Suite 102
City: Owings Mills
State: Maryland
Country: United States
Website: https://childrens-aba.org/

Amal Alrashedi Lawyers & Legal Consultants welcomes two renowned legal experts

Dubai - Amal Alrashedi Lawyers & Legal ConsultantsPerfect has announced the appointment of Dr Hassan Elhais as Legal Consultant, marking a significant expansion of the firm’s legal expertise and strengthening its international standing.

Dr Elhais brings nearly two decades of distinguished legal experience in the UAE, with particular expertise in family, criminal, and inheritance laws. Repeatedly recognised as “Legal Consultant of the Year,” he is widely regarded as a leading authority in complex family and criminal matters, including divorce, child custody and international relocation cases. Notably, he is the first and only Egyptian member of the International Academy of Family Lawyers and currently serves as Co-Chair of its Relocation Committee.

Ranked Band 1 by Chambers and Partners for Family/Matrimonial law for high net-worth individuals, Dr Elhais is also a respected legal commentator whose insights are frequently featured in leading UAE and international publications.

Also joining the firm is Mohammed Elhais, a seasoned legal professional who further strengthens the firm’s capabilities. Based in the Abu Dhabi office, he brings 30 years of experience in the legal market, including over a decade in Abu Dhabi, with a dedicated focus on civil and commercial law.

Established in 2010, Amal Alrashedi Lawyers & Legal Consultants has earned a reputation for integrity, strategic counsel and client-focused legal solutions across the UAE.

The addition of Dr Hassan Elhais and Mohammed Elhais represents a significant milestone in the firm’s continued growth, reinforcing its commitment to delivering exceptional legal expertise and comprehensive representation at the highest professional standards.

Media Contact
Company Name: ProfessionalLawyer
Contact Person: Dr Hassan Elhais – Legal Consultant
Email:Send Email
Phone: +971 4 355 8000
Country: United Arab Emirates
Website: www.professionallawyer.me

Mind Above Matter Offers Top Mental Health Solutions in Keller, TX, to Boost Well-being

mental health services Keller TX

Discover top mental health services in Keller, TX, to boost your well-being with expert care and support for a healthier, happier life.

Keller, TX - Mind Above Matter, a trusted mental health service provider in Keller, Texas, is dedicated to enhancing individuals' well-being through personalized mental health care. Offering a range of outpatient services, including therapy programs for individuals as young as 9, the organization is committed to making mental health care accessible to all.

A Compassionate Approach to Mental Health

Founded with a focus on accessibility and personalization, Mental Health Services Keller TX has quickly become a reliable name in the mental health community. The organization specializes in providing individualized outpatient therapy to people in need. Its mission is to ensure that mental health care fits seamlessly into clients' daily lives, providing the support needed for long-term healing.

“At Mind Above Matter, we are dedicated to providing care in an environment that is both supportive and familiar,” said Yossi Tress, CEO of Mind Above Matter. “Our goal is to ensure that individuals feel confident in taking control of their mental health, whether through our in-person or virtual therapy programs.”

Flexible and Accessible Therapy Programs

The organization offers a variety of flexible therapy programs designed to meet the needs of different individuals. Clients can choose from in-person outpatient group therapy or virtual therapy, both designed to fit their schedules. This flexibility helps minimize disruptions to their daily lives while maximizing the benefits of the care provided.

Mental health services Keller also address transportation challenges by providing assistance within a 20-mile radius, ensuring clients can access care with ease. This service reflects the clinic’s commitment to breaking down barriers to mental health care and ensuring that all individuals can receive the support they need.

Programs for All Ages

Keller mental health services are available to individuals of all ages, starting from 9 years old. The organization provides a range of programs designed to meet the needs of students, adults, and seniors. Specially designed programs for dual diagnoses ensure that each client’s mental health needs are addressed holistically.

One standout service is the Imatter student therapy program, which provides students with the support they need to manage their mental health while navigating academic challenges.

A Community-Oriented Commitment

Mind Above Matter is committed to serving the greater Keller area and beyond, including Tarrant, Johnson, and Dallas counties. As a community-centered organization, Mind Above Matter strives to help individuals take the first step toward improving their mental health.

About Mind Above Matter

Mind Above Matter is a leading mental health service provider in Keller, Texas. The clinic offers outpatient therapy, medication management, and virtual therapy programs for individuals aged 9 and older. The organization specializes in dual diagnosis care and the Imatter student therapy program.

Media Contact
Company Name: Mind Above Matter
Contact Person: Yossi Tress
Email:Send Email
Phone: 1 817-447-3001
Address:4232 Heritage Trace Parkway
City: Keller
State: Texas 76244
Country: United States
Website: https://mindabovematter.com/

Chronic Rhinosinusitis with Nasal Polyps Competitive Landscape Assessment 2026: FDA Approvals, Clinical trial, Emerging Therapies, Mechanism of Action, and Route of Administration | DelveInsight

Chronic Rhinosinusitis with Nasal Polyps Clinical Trial

Companies active in the Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) space include Keymed Biosciences, Connect Biopharma, AstraZeneca, Amgen, Pfizer, Trellis Bioscience LLC, GlaxoSmithKline, Gossamer Bio, Biohaven Pharmaceuticals, Insmed Incorporated, Lyra Therapeutics, and several other biotechnology and pharmaceutical innovators.

According to DelveInsight’s evaluation, more than 10 prominent pharma and biotech companies are collectively advancing over 10 pipeline candidates targeting CRSwNP. These investigational therapies span diverse molecule classes, mechanisms of action, and routes of administration. Several candidates are currently progressing through late-stage clinical trials and are expected to reach commercialization in the coming years.

The report titled “Chronic Rhinosinusitis with Nasal Polyps Pipeline Insight 2026” delivers a comprehensive analysis of clinical progress and emerging growth avenues in the CRSwNP treatment market. It provides detailed insights into pipeline assets, including mechanism of action, molecular classification, development phase, route of administration, clinical trial status, inactive programs, and regulatory milestones such as NDA approvals where relevant. The study further tracks commercial and clinical advancements from discovery to marketed products. In addition, it highlights strategic developments including partnerships, licensing deals, mergers and acquisitions, financing activities, regulatory designations, and other key product-level updates shaping the therapeutic landscape.

Get a Detailed Overview of the Chronic Rhinosinusitis with Nasal Polyps Clinical Trial Activities and Regulatory Developments in the domain @ Chronic Rhinosinusitis with Nasal Polyps Pipeline Outlook

Key Highlights from the Chronic Rhinosinusitis with Nasal Polyps Pipeline Report:

The CRSwNP treatment landscape remains dynamic, with 10+ active companies advancing more than 10 therapeutic candidates across various stages of development.
Several established and emerging players are significantly influencing the innovation ecosystem.
Promising drug candidates are progressing through mid- and late-stage clinical evaluation, demonstrating potential to address unmet medical needs.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Therapeutics Overview

Management of CRSwNP typically involves a combination of pharmacological therapy and surgical intervention, depending on disease severity and patient-specific factors. Most patients initially receive medical treatment in primary care settings before surgical options are considered. The primary therapeutic objectives include shrinking or eliminating nasal polyps, alleviating nasal obstruction, enhancing sinus drainage, restoring olfactory function, and controlling associated rhinitis symptoms. Recurrence remains a significant challenge, particularly among patients with asthma, who exhibit nearly double the recurrence risk compared to non-asthmatic individuals.

Standard treatment approaches involve intranasal and systemic corticosteroids, antihistamines, antibiotics, and non-steroidal anti-inflammatory drugs tailored to disease presentation. The U.S. FDA has approved corticosteroids and biologic therapies such as DUPIXENT, XOLAIR, and NUCALA for patients with severe CRSwNP. Additional therapeutic options include XHANCE, SINUVA, and PROPEL.

More than 10 key industry players are actively pursuing innovative CRSwNP therapies, with Keymed Biosciences emerging as a leading contributor through its advanced clinical-stage assets.

Get Detailed Insights about the Reports Offerings @ Drugs for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Treatment

Chronic Rhinosinusitis with Nasal Polyps Competitive Landscape

Major companies engaged in CRSwNP therapeutic development include:

Keymed Biosciences
Connect Biopharma
AstraZeneca
Amgen
Pfizer
Trellis Bioscience LLC
GlaxoSmithKline
Gossamer Bio
Biohaven Pharmaceuticals
Insmed Incorporated
Lyra Therapeutics
And several other emerging players

Emerging and marketed therapies featured in the report include:

CM310 – Keymed Biosciences
CBP 201 – Connect Biopharma
Additional pipeline and commercial assets

Learn More about the Clinical and Commercial Development Activities in the Chronic Rhinosinusitis with Nasal Polyps Therapeutics Domain @ Chronic Rhinosinusitis with Nasal Polyps Competitive Landscape

Chronic Rhinosinusitis with Nasal Polyps Pipeline Analysis

The report provides an in-depth evaluation of the CRSwNP therapeutic pipeline, covering:

Profiles of leading companies developing CRSwNP treatments
Assessment of early-, mid-, and late-stage pipeline candidates
Analysis of active, dormant, and discontinued programs
Evaluation of drugs based on development phase, route of administration, molecular type, target receptor, monotherapy versus combination strategies, and mechanism of action
Review of collaborations, licensing arrangements, academic partnerships, and funding initiatives shaping future market growth

Get an in-depth Assessment of the Emerging Therapies and Chronic Rhinosinusitis with Nasal Polyps Companies Actively Working in the Market @ Chronic Rhinosinusitis with Nasal Polyps Medication and FDA Approvals

Clinical Development Stages Covered in the Report

Late-stage candidates (Phase III)
Mid-stage candidates (Phase II)
Early-stage candidates (Phase I)
Preclinical and discovery-stage assets
Inactive and discontinued products

Route of Administration (ROA) Analysis

Pipeline therapies are categorized according to various administration routes, including:

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Molecule Type Classification

Pipeline candidates are segmented based on molecular class, including:

Recombinant fusion proteins
Small molecules
Monoclonal antibodies
Peptides
Polymers
Gene therapies

Request for Sample PDF to Understand More about the Chronic Rhinosinusitis with Nasal Polyps Treatment Outlook and Future Perspectives @ Chronic Rhinosinusitis with Nasal Polyps Clinical Trials and FDA Approvals

Table of Contents Overview

Introduction
Executive Summary
Current Treatment Practices
DelveInsight’s Analytical Viewpoint
Therapeutic Assessment
Phase III Products
Phase II Products
Phase I Products
Preclinical and Discovery Candidates
Inactive Products
Dormant Programs
Discontinued Products
Product Profiles
Company Profiles
Drug Profiles
Dormant and Discontinued Assets
Unmet Medical Needs
Future Market Perspectives
Analyst Insights
Appendix
Research Methodology

About DelveInsight

DelveInsight is a leading healthcare consulting and market research firm dedicated to life sciences. The company delivers comprehensive market intelligence and strategic insights, empowering pharmaceutical companies to enhance performance and make informed business decisions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Vasculitis Clinical Trials Analysis 2026: Competitive Landscape, Regulatory Updates, Emerging Therapies, Mechanisms of Action, and Routes of Administration | DelveInsight

Vasculitis Pipeline

Leading companies involved in the Vasculitis therapeutic space include R-Pharm Overseas, AbbVie, Toleranzia, Ambulero, Visterra, CytoDyn, ChemoCentryx, Hoffmann-La Roche, GlaxoSmithKline, Vifor Pharma, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, Oxitope Pharma, Eli Lilly and Company, Travere Therapeutics, Caladrius Biosciences, Yake Biotechnology, and several other global innovators.

DelveInsight’s latest publication, “Vasculitis Pipeline Insight, 2026” provides a detailed evaluation of the current clinical development landscape along with future growth opportunities within the Vasculitis market.

According to DelveInsight’s analysis, the global Vasculitis pipeline comprises more than 25 key companies developing over 30 therapeutic candidates. The report evaluates ongoing clinical trials, investigational therapies, mechanisms of action, routes of administration, and recent strategic developments shaping the treatment ecosystem.

The Vasculitis pipeline report delivers an extensive commercial and clinical assessment of investigational products spanning from preclinical research to marketed therapies. It offers comprehensive drug profiles covering mechanisms of action, clinical trial data, regulatory milestones including NDA approvals (where applicable), and development activities such as technology advancements, collaborations, mergers and acquisitions, funding initiatives, regulatory designations, and other product-specific insights.

Request for sample report @ Vasculitis Pipeline Outlook

Key Insights from the Vasculitis Pipeline Report

Companies worldwide are actively advancing innovative Vasculitis therapies, demonstrating steady clinical progress over recent years.
Major players such as R-Pharm Overseas, AbbVie, Toleranzia, Ambulero, Visterra, CytoDyn, ChemoCentryx, Hoffmann-La Roche, GlaxoSmithKline, Vifor Pharma, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, Oxitope Pharma, Eli Lilly and Company, Travere Therapeutics, Caladrius Biosciences, and Yake Biotechnology are spearheading therapeutic development.
Emerging candidates including AMB 301, BDB 1, Guselkumab, Secukinumab, and Upadacitinib are progressing through various clinical phases and are anticipated to significantly influence the Vasculitis market landscape.
In September 2025, Amgen reported findings from a Phase III open-label, single-arm study evaluating Avacopan in combination with rituximab or cyclophosphamide-based regimens in pediatric patients aged 6 to under 18 years with active ANCA-associated vasculitis (AAV).
In August 2025, Soligenix announced that the U.S. FDA’s Office of Orphan Products Development granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet’s Disease, following positive Phase IIa results demonstrating biological activity and safety.
In December 2024, Q32 Bio announced a delay in the Phase II study of ADX-097 in patients with ANCA-associated vasculitis.
Also in December 2024, Nkarta launched the Ntrust-2 clinical trial and received IND clearance for an investigator-sponsored trial assessing NKX019, its allogeneic CD19-targeted CAR-NK cell therapy, in autoimmune conditions including systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis.
In June 2024, the U.S. FDA authorized NovelMed to initiate a Phase II trial of ruxoprubart in adults with ANCA-associated vasculitis, evaluating safety and efficacy in patients with microscopic polyangiitis, granulomatosis with polyangiitis, or kidney-limited AAV.
In May 2024, Amgen shared Phase I data for AMG104/AZD8630, an inhaled anti-TSLP therapy for poorly controlled asthma, along with post-hoc analyses from the Phase III ADVOCATE study evaluating the safety and efficacy of TAVNEOS® (avacopan) in severe active ANCA-associated vasculitis with pulmonary involvement.

Vasculitis Overview

Vasculitis represents a group of rare inflammatory disorders characterized by inflammation of blood vessels, including arteries, veins, and capillaries. This inflammation may result in vessel wall thickening, narrowing, weakening, or scarring, potentially impairing blood flow to vital organs. Vasculitis may present as either acute or chronic and can arise as a primary autoimmune condition or secondary to infections, medications, or systemic diseases.

Common forms include Giant Cell Arteritis, Granulomatosis with Polyangiitis, Takayasu Arteritis, Polyarteritis Nodosa, and Henoch–Schönlein Purpura. Clinical manifestations vary by organ involvement but frequently include fatigue, fever, weight loss, musculoskeletal pain, dermatological symptoms, neurological complications, and respiratory issues.

Diagnosis typically involves laboratory testing (including ANCA assays), imaging modalities, tissue biopsy, and specialized assessments. Standard treatment strategies focus on corticosteroids and immunosuppressive agents to control inflammation and prevent organ damage. Early diagnosis and prompt intervention remain critical to improving patient outcomes and reducing complications.

Get a Free Sample PDF Report to know more about Vasculitis Pipeline Therapeutic Assessment - https://www.delveinsight.com/report-store/vasculitis-pipeline-insight

Emerging Vasculitis Therapies in Clinical Development

AMB 301 – Ambulero
BDB 1 – Beijing Defengrei Biotechnology
Guselkumab – Janssen Biotech
Secukinumab – Novartis
Upadacitinib – AbbVie

Route of Administration Analysis

The pipeline report categorizes investigational therapies based on their route of administration, including:

Oral
Subcutaneous
Intravenous
Intramuscular

Molecule Type Segmentation

Vasculitis pipeline candidates are classified by molecular type, such as:

Bispecific antibodies
Peptides
Small molecules
Gene therapies

Comprehensive Vasculitis Therapeutics Assessment

The report includes:

Evaluation by product type
Analysis by stage of development and product category
Assessment by route of administration
Stage-wise segmentation by administration route
Classification by molecule type
Stage-wise molecule type analysis

DelveInsight’s report encompasses more than 30 therapeutic candidates across multiple development stages, including Phase III, Phase II, Phase I, preclinical, discovery-stage, inactive, and discontinued programs.

Further Vasculitis product details are provided in the report. Download the Vasculitis pipeline report to learn more about the emerging Vasculitis therapies

Vasculitis Pipeline Analysis

The report provides:

Detailed company-wise pipeline evaluation
Stage-based segmentation of therapeutic candidates
Insights into active and dormant programs
Drug analysis based on development phase, target receptor, mechanism of action, route of administration, monotherapy versus combination therapy, and molecular class
Comprehensive review of strategic collaborations, licensing agreements, partnerships, and funding activities

The research methodology integrates proprietary databases, company disclosures, clinical trial registries, investor presentations, conference proceedings, SEC filings, and credible third-party industry sources.

Download Sample PDF Report to know more about Vasculitis drugs and therapies

Vasculitis Pipeline Market Drivers

Increasing disease awareness and improved diagnostic capabilities
Growing focus on rare and orphan indications
Advances in immunology and targeted biologic therapies
Strong clinical research engagement from over 25 companies
Supportive regulatory and reimbursement precedents

Vasculitis Pipeline Market Challenges

Heterogeneous disease subtypes requiring targeted drug development
Recruitment difficulties due to rare patient populations
Continued reliance on off-label immunosuppressants
Long-term safety considerations with biologics
High therapy costs limiting accessibility in certain regions

Scope of the Vasculitis Pipeline Insight

Coverage: Global
Key Vasculitis Companies: R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics, Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and others.
Key Vasculitis Therapies: AMB 301, BDB 1, Guselkumab, Secukinumab, Upadacitinib, and others
Vasculitis Therapeutic Assessment: Vasculitis current marketed and Vasculitis emerging therapies
Vasculitis Market Dynamics: Vasculitis market drivers and Vasculitis market barriers

Request for Sample PDF Report for Vasculitis Pipeline Assessment and clinical trials

Table of Contents

Introduction
Executive Summary
Disease Overview
Commercial Assessment
Pipeline Therapeutics
Late-Stage Products
Mid-Stage Products
Early-Stage Products
Preclinical Candidates
Therapeutic Assessment
Inactive Programs
Collaboration Analysis
Key Companies
Key Products
Unmet Needs
Market Drivers and Barriers
Future Outlook
Analyst Perspectives
Appendix
About DelveInsight

About DelveInsight

DelveInsight is a leading life sciences-focused business consulting and market research firm. The company provides comprehensive strategic solutions to pharmaceutical and biotechnology organizations, supporting performance enhancement through data-driven insights, healthcare consulting services, and practical market intelligence to accelerate growth and address industry challenges effectively.

Diagnostic Imaging Equipment Market to Reach USD 82.26 Billion by 2034, Growing at 5.39% CAGR from 2026-2034 Amid Rising Chronic Disease Burden and AI-Driven Innovation, analyses DelveInsight

Diagnostic Imaging Equipment Market

The global diagnostic imaging equipment market is projected to grow from USD 51,560.07 million in 2025. Also, Market growth is largely attributed to the increasing burden of chronic illnesses such as cardiovascular diseases, cancer, neurological disorders, and orthopedic conditions, all of which require timely and precise diagnostic imaging.

Diagnostic imaging equipment market report offers a comprehensive overview of the global diagnostic imaging equipment market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, and Others), Application (Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, and Others), End-User (Hospitals, Diagnostic Imaging Centres, and Others), and geography.

Discover Growth Opportunities in the $82.26 Billion Diagnostic Imaging Equipment Market – Get Instant Access Now - Diagnostic Imaging Equipment Market Forecast

Key participants operating in the diagnostic imaging equipment market include Siemens Healthineers, GE HealthCare, Philips Healthcare, Canon Medical Systems Corporation, Hitachi Medical Systems, Hologic, Shimadzu Corporation, Fujifilm Medical Systems, Carestream Health, Agfa-Gevaert Group, Esaote SpA, Samsung Healthcare, Konica Minolta Healthcare, Varian Medical Systems, Ziehm Imaging GmbH, Mindray Medical International Limited, Planmed Oy, Analogic Corporation, Neusoft Medical Systems Co., Ltd., and other established players.

North America is expected to lead the global diagnostic imaging equipment market, supported by its advanced healthcare infrastructure, strong healthcare expenditure, and early adoption of cutting-edge imaging technologies. The region benefits from the presence of leading manufacturers, continuous product innovation, and rapid integration of AI-driven digital imaging into routine clinical workflows. A high prevalence of chronic diseases, favorable reimbursement policies, a growing elderly population, and strong government-backed research initiatives further reinforce its dominant position. The focus on early diagnosis and preventive healthcare, combined with a skilled medical workforce, continues to solidify North America’s leadership.

Within the product segment, Magnetic Resonance Imaging (MRI) systems are projected to capture the largest market share in 2025 due to their ability to deliver high-resolution, non-invasive, radiation-free imaging of soft tissues and organs.

Diagnostic Imaging Equipment Market Size and Forecast

2025 Market Size: USD 51,560.07 million
2034 Projected Market Size: USD 82,258.46 million
Growth Rate (2026–2034): 5.39% CAGR
Largest Market: North America
Fastest Growing Market: Asia-Pacific
Market Structure: Moderately to Highly Concentrated

Download the Diagnostic Imaging Equipment Market Report Sample for Detailed Market Size, CAGR, and 2034 Forecast Insights - https://www.delveinsight.com/sample-request/diagnostic-imaging-equipment-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Key Diagnostic Imaging Equipment Growth Drivers

Rising Chronic Disease Burden and Aging Population The growing incidence of cancer, cardiovascular disorders, neurological diseases, and musculoskeletal conditions, along with an aging population, is significantly increasing demand for advanced diagnostic imaging systems. Elderly patients and individuals with chronic illnesses require frequent monitoring, fueling adoption of MRI, CT, ultrasound, and X-ray technologies for early detection and effective disease management.

Technological Innovation Accelerating Market Expansion Rapid advancements such as AI-enabled imaging, 3D/4D visualization, portable devices, and enhanced-resolution systems are improving diagnostic precision and workflow efficiency. These innovations are enabling quicker and more reliable diagnoses across hospitals and outpatient facilities worldwide.

Increased Product Development Initiatives Leading companies are continuously investing in R&D to introduce next-generation imaging systems. AI-integrated platforms, helium-free MRI systems, compact scanners, and improved image reconstruction technologies are enhancing clinical outcomes and expanding the application scope of imaging modalities globally.

Diagnostic Imaging Equipment Market Segmentation Overview

The diagnostic imaging equipment market is segmented by:

Product: X-ray systems, CT scanners, ultrasound systems, MRI systems, nuclear imaging systems, mammography systems, and others
Application: Cardiology, oncology, neurology, orthopedics, gastroenterology, gynecology, and others
End-User: Hospitals, diagnostic imaging centers, and others
Geography: North America, Europe, Asia-Pacific, and Rest of the World

The report provides detailed insights into competitive dynamics, regulatory frameworks, and emerging opportunities across major global markets.

Request Comprehensive MRI, CT, Ultrasound, and X-Ray Imaging Market Analysis with Competitive Landscape Data - Diagnostic Imaging Equipment Competitive Landscape

Diagnostic Imaging Equipment Market Dynamics And Trends

The market has experienced notable growth driven by rising disease prevalence, rapid technological innovation, and increased product launches. According to global cancer statistics from the International Agency for Research on Cancer (2026), approximately 21.3 million new cancer cases were estimated in 2025, with projections reaching 32.6 million by 2045. Imaging technologies such as MRI, CT, PET, and ultrasound remain critical in tumor detection, staging, biopsy guidance, and treatment monitoring.

Similarly, data from the Institute for Health Metrics and Evaluation (2024) indicates that osteoarthritis affects 15% of individuals over 30 worldwide, necessitating imaging for accurate assessment and disease progression monitoring.

Technological breakthroughs continue to reshape the market. For instance, in January 2025, Siemens Healthineers introduced the MAGNETOM Flow 1.5T MRI platform with Dry Cool technology, significantly reducing helium usage and enhancing sustainability. These advancements, particularly AI integration and scan-time reduction, are accelerating clinical adoption.

However, challenges such as radiation exposure risks from CT and X-ray modalities and stringent regulatory approval processes may moderate growth during the forecast period.

Diagnostic Imaging Equipment Segment Insights

By Product: MRI Systems Lead Growth MRI systems are projected to grow at the fastest CAGR of 6.41% between 2026 and 2034. Their superior soft tissue visualization, absence of ionizing radiation, and expanding applications in oncology, neurology, cardiology, and musculoskeletal imaging are driving adoption. Innovations such as 3T MRI, functional MRI (fMRI), AI-powered reconstruction, and wide-bore systems are enhancing performance and patient comfort.

By Application: Cardiology Dominates Cardiology remains a key revenue-generating segment due to the global burden of cardiovascular diseases. Advanced modalities such as cardiac MRI, CT angiography, echocardiography, and hybrid imaging systems enable accurate diagnosis and treatment planning.

By End-User: Hospitals Hold Largest Share Hospitals account for the largest market share, driven by high patient volumes, availability of skilled professionals, favorable reimbursement, and investments in advanced imaging infrastructure.

Diagnostic Imaging Equipment Regional Insights

North America diagnostic imaging equipment market is expected to account for 41% of the global market in 2025, driven by advanced infrastructure, high healthcare spending, and widespread AI adoption.

Europe diagnostic imaging equipment market benefits from strong government healthcare support, aging demographics, and rising musculoskeletal and chronic disease cases.

Asia-Pacific diagnostic imaging equipment market is emerging as the fastest-growing market, supported by expanding healthcare infrastructure, rising cancer prevalence in countries like India and China, and increasing public and private sector investments.

Get In-Depth North America and Asia-Pacific Diagnostic Imaging Equipment Market Trends & Growth Projections @ Diagnostic Imaging Equipment Market Analysis and Dynamics

Diagnostic Imaging Equipment Competitive Landscape

The diagnostic imaging equipment market is moderately to highly consolidated, with major global players competing through innovation, AI integration, product differentiation, partnerships, and geographic expansion. High capital investment requirements, regulatory compliance, and service network development act as barriers to entry. Meanwhile, regional players are gaining momentum in cost-sensitive markets by offering affordable and portable imaging solutions.

Strategic mergers, acquisitions, and collaborations continue to redefine competitive dynamics, influencing pricing strategies and long-term growth initiatives.

Recent Developments in diagnostic imaging equipment market

CE Mark approval for Seno Medical’s Imagio® Imaging System (January 2026)
FDA clearance for Hyperfine’s Swoop® portable MRI system (June 2025)
Launch of helium-free MRI innovations by Philips (November 2024)
Introduction of AI-powered cardiovascular ultrasound applications by Philips (June 2024)

Access AI-Powered Imaging Systems Market Insights, Emerging Technology Trends, and Regulatory Updates - https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr

Analyst Commentary on diagnostic imaging equipment

The diagnostic imaging equipment market is set for sustained expansion through 2034, supported by increasing chronic disease prevalence, rapid technological advancements, growing geriatric populations, and expanding healthcare infrastructure globally. While regulatory complexities and radiation-related concerns pose challenges, continuous innovation and strategic investments by key industry players are expected to maintain strong long-term growth momentum.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Juvenile Idiopathic Arthritis Market Poised to Grow at 5.6% CAGR Through 2036 | DelveInsight

Juvenile Idiopathic Arthritis Market

Leading Juvenile Idiopathic Arthritis Companies include Bristol-Myers Squibb, UCB Biopharma, Novartis, AbbVie, Sanofi, Regeneron Pharmaceuticals, Janssen Pharmaceutical, Eli Lilly, Sobi, Pfizer, and others

The Juvenile Idiopathic Arthritis (JIA) market is witnessing consistent expansion, fueled by increasing disease awareness, better diagnostic approaches, and broader access to advanced biologic treatments. The anticipated introduction of innovative therapies such as SOTYKTU from Bristol-Myers Squibb, BIMZELX from UCB Biopharma, MAS825 from Novartis, and others is expected to further accelerate market growth.

DelveInsight’s latest Juvenile Idiopathic Arthritis Market Insights report delivers a detailed evaluation of current treatment practices, emerging therapies, individual drug market shares, and market size projections from 2022 to 2036. The study covers the 7MM, including the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Discover which regions are driving the fastest JIA market growth @ Juvenile Idiopathic Arthritis Market Forecast

Juvenile Idiopathic Arthritis Market Overview

DelveInsight estimates the JIA market size in the 7MM at approximately USD 2.3 billion in 2025.
The United States represented the largest share among major markets in 2025, surpassing the EU4, the UK, and Japan.
Total prevalent JIA cases across the 7MM were about 142,000 in 2025, projected to rise to nearly 173,000 by 2036.
Leading players such as Bristol-Myers Squibb, UCB Biopharma, Novartis, and others are advancing next-generation JIA therapies expected to enter the market in the coming years.
Notable investigational treatments include Deucravacitinib (SOTYKTU), Bimekizumab (BIMZELX), and MAS825.
In Japan, adalimumab is anticipated to command the highest market share by 2036.

Key Growth Drivers of the Juvenile Idiopathic Arthritis Market

Rising Disease Prevalence

DelveInsight reports approximately 141,800 prevalent JIA cases in 2025 across the 7MM, forecasted to increase to around 173,000 by 2036, reflecting a CAGR of 1.8%.

Therapeutic Advancements

The shift toward biologics and targeted therapies including IL-6 inhibitors and JAK inhibitors is transforming JIA management by improving remission outcomes and patient quality of life.

Launch of Emerging Therapies

Upcoming launches of SOTYKTU, BIMZELX, MAS825, and similar therapies are expected to significantly reshape market dynamics over the forecast period.

According to Aparna Thakur, Assistant Project Manager, Forecasting and Analytics at DelveInsight, the JIA treatment paradigm is transitioning from broad immunosuppressive approaches to precision-targeted agents. JAK inhibitors and interleukin-targeted therapies are gaining traction due to favorable efficacy, safety, and expanded pediatric indications.

Discover more about which new or emerging therapies are expected to shape the JIA market @ Juvenile Idiopathic Arthritis Drugs

Juvenile Idiopathic Arthritis Market Analysis

The JIA treatment landscape is evolving after years dominated by traditional immunosuppressants and stepwise empirical therapy. Approvals and expanding utilization of targeted therapies such as upadacitinib (RINVOQ) and sarilumab (KEVZARA) validate pathway-specific strategies and encourage innovation within the pipeline.

Upadacitinib (RINVOQ), a next-generation JAK inhibitor, has demonstrated meaningful benefits in managing pediatric inflammatory activity. Its success reinforces confidence in precision immunomodulation and is expected to stimulate further R&D investments.

Emerging biologics and targeted agents—including deucravacitinib, bimekizumab, and MAS825—mirror therapeutic trends seen in other immune-mediated and rare inflammatory disorders, where early targeted approvals catalyze broader pipeline expansion.

The United States remains the largest JIA market, supported by higher diagnosis rates, earlier biologic adoption, and faster uptake of innovative therapies compared to Europe and Japan. Continued first-in-class launches, enhanced genetic testing, and growing disease awareness are projected to sustain market growth through 2036.

Download the report to understand who are the top pharmaceutical companies in juvenile idiopathic arthritis @ Juvenile Idiopathic Arthritis Market Analysis

Juvenile Idiopathic Arthritis Competitive Landscape

Prominent pipeline candidates include SOTYKTU (Bristol-Myers Squibb), BIMZELX (UCB Biopharma), MAS825 (Novartis), and others.

SOTYKTU (Deucravacitinib) – Bristol-Myers Squibb

SOTYKTU is an oral, selective TYK2 inhibitor utilizing a distinct allosteric mechanism. It represents a new class of small-molecule therapies designed to selectively block TYK2-mediated pathways, including IL-23, IL-12, and type I interferons. Its specificity allows inhibition of TYK2 without impacting JAK1, JAK2, or JAK3 at therapeutic levels.

Bimekizumab (BIMZELX) – UCB Biopharma

Bimekizumab is a humanized IgG1 monoclonal antibody that neutralizes both IL-17A and IL-17F—key inflammatory cytokines. The therapy is currently in Phase III development.

The expected commercialization of these advanced therapies is likely to redefine the JIA treatment paradigm, establishing new standards of care and fostering medical innovation and economic growth.

Recent Juvenile Idiopathic Arthritis Market Developments

September 2025: AbbVie filed for label expansion of upadacitinib in Japan for pJIA inadequately controlled by current therapies.
July 2025: The FDA accepted the supplemental NDA for deucravacitinib in psoriatic arthritis, assigning a PDUFA date of March 6, 2026.

Download free sample report to know in details about Juvenile Idiopathic Arthritis market size and share analysis @ Juvenile Idiopathic Arthritis Market Analysis

About Juvenile Idiopathic Arthritis

Juvenile idiopathic arthritis is a chronic autoimmune disorder characterized by persistent joint inflammation in children under 16. The immune system mistakenly attacks healthy tissues, causing joint pain, swelling, stiffness, and mobility limitations. Disease severity varies widely and may involve one or multiple joints. Although its exact cause remains unclear, genetic and environmental factors are believed to contribute. Early diagnosis and treatment are essential to prevent long-term joint damage and support normal growth and development.

Juvenile Idiopathic Arthritis Epidemiology Insights

The epidemiology section outlines historical and forecasted patient trends across key markets. In the United States, approximately 34,000 diagnosed cases in 2025 were male, while females accounted for about 66%, reflecting greater female susceptibility.

The report segments epidemiological analysis (2022–2036) into:

Total prevalent cases
Subtype-specific prevalence
Gender-specific prevalence
Treatment-eligible population

Download free sample report to know in details about emerging drugs and clinical trial @ Juvenile Idiopathic Arthritis Clinical Trial and FDA Approvals

Scope of the Report

Study Period: 2022–2036
Coverage: 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Juvenile Idiopathic Arthritis Market CAGR: 5.6 %
Juvenile Idiopathic Arthritis Market Size in 2025: USD 2.3 Billion
Key Juvenile Idiopathic Arthritis Companies: Bristol-Myers Squibb (NYSE: BMY), UCB Biopharma (EBR: UCB), Novartis (SWX: NOVN), AbbVie (NYSE: ABBV), Sanofi (EPA: SAN), Regeneron Pharmaceuticals (NASDAQ: REGN), Janssen Pharmaceutical, Eli Lilly (NYSE: LLY), Sobi (STO: SOBI), Pfizer (NYSE: PFE), and others
Key Juvenile Idiopathic Arthritis Therapies: Deucravacitinib (SOTYKTU), Bimekizumab (BIMZELX), MAS825, RINVOQ, KEVZARA, TREMFYA, COSENTYX, ORENCIA, CIMZIA, ILARIS, SIMPONI ARIA, OLUMIANT, TALTZ, KINERET, XELJANZ, and others

About DelveInsight